Developer docs
API playgroundTry for free, no card

Search company profiles

OBI Pharma

Full company profile

uuid00075m9

Namestring
OBI Pharma
Legal namestring
OBI Pharma, Inc.
Websiteurl
obipharma.com
Company typeenum
Public
Founded yearint
2002
Descriptiontext

OBI Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Taipei, Taiwan and listed on the Taipei Exchange (4174.TWO). Founded in 2002, the company has refocused its strategy on developing antibody-drug conjugates (ADCs) for cancer treatment, following the 2025 termination of its earlier Globo H immunotherapy programs. OBI serves two principal customer segments: (i) cancer patients with solid tumors and hematological malignancies targeted through OBI's clinical-stage drug candidates, and (ii) global pharmaceutical partners who license OBI's ADC products and platform technologies for co-development or commercialization.

OBI's core technology is the Obrion® ADC Technology Platform, a modular system for next-generation drug conjugation built around five proprietary sub-platforms: GlycOBI® (glycan site-specific conjugation), GlycOBI DUO® (dual-payload conjugation), ThiOBI® (cysteine-based conjugation for nanobodies, fragments, and peptides), EndoSymeOBI® (proprietary enzymatic glycan remodeling), and HYPrOBI® (hydrophilic linker with masking and shielding effects). Together these enable site-specific, homogenous ADC generation with tunable drug-to-antibody ratios from DAR2 to DAR16. The clinical pipeline targets validated oncology biomarkers including TROP2 (OBI-992, OBI-902), Nectin-4 (OBI-904), HER2, cMET, and HER3, with OBI-992 in Phase I/II and OBI-902 having entered Phase I/II in August 2025. Several candidates have received FDA Orphan Drug Designations.

OBI generates revenue exclusively through licensing royalties, one-time license fees, and collaboration payments, as it has no commercialized products. The company is publicly traded, has approximately 140 employees, and operates through wholly- or majority-owned subsidiaries in the US (OBI Pharma USA, Inc.) and Australia (OBI Pharma Australia Pty Ltd), as well as majority-owned biotech and cosmetic-medicine entities (Amaran Biotechnology, Obigen Pharma, AP Biosciences). Recent licensing and collaboration deals with TegMine Therapeutics, AP Biosciences, GlyTech, Ascentawits, and Zhejiang Hisun Pharmaceutical demonstrate a partnership-led commercialization model across North America, Greater China, and Japan.

Short descriptiontext

OBI Pharma is a Taipei-based, Taipei Exchange-listed clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer using its proprietary Obrion® platform (GlycOBI®, ThiOBI®, HYPrOBI®), generating revenue through licensing and partnerships with global pharma rather than product sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersTaipei, Taiwan
HQ citystring
Taipei
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, oncology therapeutics, ADC technology platform, cancer drug development, biopharmaceutical research
Industry1 code
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Biopharmaceuticals (Antibody-Drug Conjugates)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Collaboration Revenue
TypeLicensing Royalties
Description

OBI Pharma generates revenue through out-licensing its ADC products and proprietary platform technologies to global pharmaceutical partners. The company has signed licensing agreements with partners including TegMine Therapeutics for glycan-targeting ADC, and maintains collaboration agreements with AP Biosciences and others.

obipharma.com
2No Commercialized Products
TypeOne Time License
Description

As a clinical-stage oncology company, OBI Pharma has no commercialized products generating revenue. All products are in development stage (preclinical through Phase 2).

obipharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OBI Pharma is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and prodrugs for oncology indications. Its proprietary Obrion® ADC platform and sub-platforms (GlycOBI®, GlycOBI DUO®, ThiOBI®, EndoSymeOBI®, HYPrOBI®) enable site-specific conjugation and controlled DAR for homogeneous ADCs. Lead programs include OBI-992, OBI-902 (TROP2 ADCs), OBI-3424 (AKR1C3 prodrug), OBI-999 and OBI-888 (Globo H ADCs).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • OBI-992 reached putative Recommended Phase 2 Dose (pRP2D) in Phase 1/2 study
+2 more records
Product and service6 records
1OBI-992
CategoryAntibody-Drug Conjugate (ADC) — Oncology Pipeline Asset
Description

TROP2-targeted antibody-drug conjugate in clinical development by OBI Pharma for oncology indications.

2OBI-902
CategoryAntibody-Drug Conjugate (ADC) — Oncology Pipeline Asset
Description

TROP2-targeted antibody-drug conjugate in clinical development by OBI Pharma for oncology indications.

3OBI-3424
CategoryProdrug — Oncology Pipeline Asset
Description

AKR1C3-activated prodrug (small molecule) in clinical development by OBI Pharma for oncology indications.

4OBI-999
CategoryAntibody-Drug Conjugate (ADC) — Oncology Pipeline Asset
Description

Globo H-targeted antibody-drug conjugate developed by OBI Pharma for oncology indications.

5OBI-888
CategoryAntibody-Drug Conjugate (ADC) — Oncology Pipeline Asset
Description

Globo H-targeted antibody-drug conjugate developed by OBI Pharma for oncology indications.

6Obrion® ADC Technology Platform (including GlycOBI®, GlycOBI DUO®, ThiOBI®, EndoSymeOBI®, HYPrOBI® sub-platforms)
CategoryADC Technology Platform (Licensed Platform)
Description

Proprietary modular ADC technology platform offered by OBI Pharma for licensing to global pharmaceutical partners, enabling site-specific conjugation, controlled DAR, and improved ADC stability.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-12-19
Description

OBI Pharma signed an exclusive global license agreement with TegMine Therapeutics for a glycan-targeting ADC. This follows the successful delivery of a commissioned ADC candidate, advancing the collaboration between OBI and TegMine. OBI provides its GlycOBI® enabling technology while TegMine contributes antibodies targeting cancer-associated glycans.

2AP Biosciences
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-03
Description

OBI Pharma signed a Material Transfer and Technology Development Agreement (MTA) with AP Biosciences to develop next-generation bispecific Antibody-Drug Conjugates (ADCs). AP Biosciences provides a bispecific antibody (BsAb) while OBI Pharma contributes its GlycOBI® glycan-conjugation technology platform.

obipharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-06
Description

OBI Pharma entered into a Master Services Agreement with TegMine Therapeutics for ADC-related collaboration. TegMine specializes in developing best-in-class antibodies targeting cancer glycans and glycoproteins. The collaboration utilizes OBI's GlycOBI® and TegMine's TegMiner™ enabling technologies.

4Ascentawits
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

OBI-3424 is under clinical evaluation in collaboration with Ascentawits. Ascentawits has completed enrollment in a single-arm phase II trial in HCC and initiated a phase IIb study in HCC. OBI acquired worldwide rights from Threshold Pharmaceuticals except for rights in Taiwan, Japan, South Korea, Singapore, Malaysia, Thailand, Turkey, India which are owned by Ascentawits as AST-3424.

obipharma.com
5GlyTech
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-12-23
Description

Signed marketing promotion and material transfer agreement with Japan's GlyTech for GlycOBI® ADC key technology in the Japanese market. GlyTech serves as a marketing promotion partner for OBI's technology platform in Japan.

obipharma.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-01-01
Description

OBI Pharma licensed 'Nectin-4 Human Antibody' rights from Ablexis, LLC in 2023. This enables OBI's development of Nectin-4 targeted ADCs including OBI-904.

7Biosion, Inc.
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-12-01
Description

OBI signed an exclusive license agreement for anti-TROP2 humanized monoclonal antibody (BSI04702) with Biosion for worldwide rights excluding China, Hong Kong and Macao. OBI has licensed the TROP2 targeting antibody amino acid sequence since December 2021. OBI holds worldwide commercial rights to OBI-902 and OBI-992 except for rights pertaining to the antibody in China.

obipharma.com
8Zhejiang Hisun Pharmaceutical Co. Ltd.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on OBI-3424/AST-3424 development in China. Zhejiang Hisun Pharmaceutical holds rights in China, Hong Kong, Macao for OBI-3424/AST-3424 and has initiated a phase IIb study in HCC in collaboration with Ascentawits.

obipharma.com
Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ADC company with proprietary conjugation technology and pipeline targeting validated oncology antigens (FRα, HER2, HER3). Closely comparable to OBI in pipeline architecture, antigen selection, and platform-based approach.

TypeEmerging player
Description

China-headquartered biopharmaceutical company developing next-generation ADCs (IBI354, IBI130, IBI3001) with global out-licensing ambitions. Comparable as an Asia-based clinical-stage ADC developer with platform-out-licensing strategy.

TypeBroad incumbent
Description

Japanese pharma leader behind the DXd ADC platform (Enhertu, Datroway with AstraZeneca). Sets the competitive benchmark for site-specific ADCs that OBI's GlycOBI® platform competes against; relevant for licensing economics and partnership dynamics.

TypeDirect peer
Description

Clinical-stage oncology company developing immune-stimulating ADCs (ISACs), a related next-generation ADC category. Comparable in clinical stage, target oncology focus, and platform-technology licensing model.

TypeDirect peer
Description

Clinical-stage ADC and antibody-drug conjugate developer with a pipeline targeting solid tumors. Closely comparable in stage, business model (out-licensing and platform partnerships), and focus on site-specific conjugation approaches.

6Hansoh Pharmaceutical
TypeEmerging player
Description

Chinese pharma with growing ADC pipeline and global BD ambitions (multiple licensing deals with big pharma in oncology). Comparable as an Asia-based emerging ADC developer pursuing similar out-licensing and partnership strategies.

TypeBroad incumbent
Description

Global pharma with major ADC franchise post-Seagen acquisition (Adcetris, Padcev, Tukysa, Tivdak). Competes directly for ADC licensing deals and represents a likely strategic acquirer or large-pharma partner for clinical-stage ADC developers.

TypeDirect peer
Description

Clinical-stage ADC developer with proprietary Dolasynthen and Immunosynthen platforms targeting oncology. Comparable as a similarly-sized clinical-stage biotech focused exclusively on next-generation ADC conjugation technologies with no commercialized products.

TypeDirect peer
Description

Clinical-stage ADC biotech focused on differentiated conjugation chemistry and linker technologies, with lead candidates in solid tumors. Directly comparable on enabling-technology positioning and clinical-stage ADC focus.

TypeBroad incumbent
Description

Global pharma with major ADC franchise via Daiichi Sankyo partnership (Enhertu, Datroway). Represents both a potential licensor/partner for OBI's platform and a competitor pursuing similar TROP2, HER2, and HER3 targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OBI Pharma

Oncology Biopharmaceuticals (Antibody-Drug Conjugates)obipharma.com

OBI Pharma is a Taipei-based, Taipei Exchange-listed clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer using its proprietary Obrion® platform (GlycOBI®, ThiOBI®, HYPrOBI®), generating revenue through licensing and partnerships with global pharma rather than product sales.

What OBI Pharma does

OBI Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Taipei, Taiwan and listed on the Taipei Exchange (4174.TWO). Founded in 2002, the company has refocused its strategy on developing antibody-drug conjugates (ADCs) for cancer treatment, following the 2025 termination of its earlier Globo H immunotherapy programs. OBI serves two principal customer segments: (i) cancer patients with solid tumors and hematological malignancies targeted through OBI's clinical-stage drug candidates, and (ii) global pharmaceutical partners who license OBI's ADC products and platform technologies for co-development or commercialization.

OBI's core technology is the Obrion® ADC Technology Platform, a modular system for next-generation drug conjugation built around five proprietary sub-platforms: GlycOBI® (glycan site-specific conjugation), GlycOBI DUO® (dual-payload conjugation), ThiOBI® (cysteine-based conjugation for nanobodies, fragments, and peptides), EndoSymeOBI® (proprietary enzymatic glycan remodeling), and HYPrOBI® (hydrophilic linker with masking and shielding effects). Together these enable site-specific, homogenous ADC generation with tunable drug-to-antibody ratios from DAR2 to DAR16. The clinical pipeline targets validated oncology biomarkers including TROP2 (OBI-992, OBI-902), Nectin-4 (OBI-904), HER2, cMET, and HER3, with OBI-992 in Phase I/II and OBI-902 having entered Phase I/II in August 2025. Several candidates have received FDA Orphan Drug Designations.

OBI generates revenue exclusively through licensing royalties, one-time license fees, and collaboration payments, as it has no commercialized products. The company is publicly traded, has approximately 140 employees, and operates through wholly- or majority-owned subsidiaries in the US (OBI Pharma USA, Inc.) and Australia (OBI Pharma Australia Pty Ltd), as well as majority-owned biotech and cosmetic-medicine entities (Amaran Biotechnology, Obigen Pharma, AP Biosciences). Recent licensing and collaboration deals with TegMine Therapeutics, AP Biosciences, GlyTech, Ascentawits, and Zhejiang Hisun Pharmaceutical demonstrate a partnership-led commercialization model across North America, Greater China, and Japan.

OBI Pharma firmographics

Firmographics
Name
OBI Pharma
Legal name
OBI Pharma, Inc.
Website
https://obipharma.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
101–250 employees
Short description
OBI Pharma is a Taipei-based, Taipei Exchange-listed clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer using its proprietary Obrion® platform (GlycOBI®, ThiOBI®, HYPrOBI®), generating revenue through licensing and partnerships with global pharma rather than product sales.
Ownership category
akta.pro rank

OBI Pharma industry classification

Industry
Product category
Oncology Biopharmaceuticals (Antibody-Drug Conjugates)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody-drug conjugates
  • Oncology therapeutics
  • ADC technology platform
  • Cancer drug development
  • Biopharmaceutical research

Where OBI Pharma is headquartered

Location

Headquarters

HQ city
Taipei
HQ country
Taiwan
HQ region
Asia

Offices3 records

Markets served

OBI Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Collaboration Revenue: OBI Pharma generates revenue through out-licensing its ADC products and proprietary platform technologies to global pharmaceutical partners. The company has signed licensing agreements with partners including TegMine Therapeutics for glycan-targeting ADC, and maintains collaboration agreements with AP Biosciences and others.
  2. No Commercialized Products: As a clinical-stage oncology company, OBI Pharma has no commercialized products generating revenue. All products are in development stage (preclinical through Phase 2).

Go-to-market motion1 record

Marketing channels5 records

OBI Pharma product offering

Product offering

Core offering

OBI Pharma is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and prodrugs for oncology indications. Its proprietary Obrion® ADC platform and sub-platforms (GlycOBI®, GlycOBI DUO®, ThiOBI®, EndoSymeOBI®, HYPrOBI®) enable site-specific conjugation and controlled DAR for homogeneous ADCs. Lead programs include OBI-992, OBI-902 (TROP2 ADCs), OBI-3424 (AKR1C3 prodrug), OBI-999 and OBI-888 (Globo H ADCs).

Differentiator

Problem solved

Functional benefit

Products and services

  • OBI-992 TROP2-targeted antibody-drug conjugate in clinical development by OBI Pharma for oncology indications.
  • OBI-902 TROP2-targeted antibody-drug conjugate in clinical development by OBI Pharma for oncology indications.
  • OBI-3424 AKR1C3-activated prodrug (small molecule) in clinical development by OBI Pharma for oncology indications.
  • OBI-999 Globo H-targeted antibody-drug conjugate developed by OBI Pharma for oncology indications.
  • OBI-888 Globo H-targeted antibody-drug conjugate developed by OBI Pharma for oncology indications.
  • Obrion® ADC Technology Platform (including GlycOBI®, GlycOBI DUO®, ThiOBI®, EndoSymeOBI®, HYPrOBI® sub-platforms) Proprietary modular ADC technology platform offered by OBI Pharma for licensing to global pharmaceutical partners, enabling site-specific conjugation, controlled DAR, and improved ADC stability.

Quantifiable outcome

  • OBI-992 reached putative Recommended Phase 2 Dose (pRP2D) in Phase 1/2 study
  • +2 more outcomes

Companies that use OBI Pharma

Customer profile

Segments3 records

Ideal customer profiles1 record

OBI Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

OBI Pharma partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • TegMine TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 19 December 2025OBI Pharma signed an exclusive global license agreement with TegMine Therapeutics for a glycan-targeting ADC. This follows the successful delivery of a commissioned ADC candidate, advancing the collaboration between OBI and TegMine. OBI provides its GlycOBI® enabling technology while TegMine contributes antibodies targeting cancer-associated glycans.
  • AP BiosciencescoreStrategic or Co-development Partner · 3 September 2025OBI Pharma signed a Material Transfer and Technology Development Agreement (MTA) with AP Biosciences to develop next-generation bispecific Antibody-Drug Conjugates (ADCs). AP Biosciences provides a bispecific antibody (BsAb) while OBI Pharma contributes its GlycOBI® glycan-conjugation technology platform.
  • TegMine TherapeuticscoreStrategic or Co-development Partner · 6 June 2025OBI Pharma entered into a Master Services Agreement with TegMine Therapeutics for ADC-related collaboration. TegMine specializes in developing best-in-class antibodies targeting cancer glycans and glycoproteins. The collaboration utilizes OBI's GlycOBI® and TegMine's TegMiner™ enabling technologies.
  • AscentawitscoreStrategic or Co-development Partner · 1 January 2025OBI-3424 is under clinical evaluation in collaboration with Ascentawits. Ascentawits has completed enrollment in a single-arm phase II trial in HCC and initiated a phase IIb study in HCC. OBI acquired worldwide rights from Threshold Pharmaceuticals except for rights in Taiwan, Japan, South Korea, Singapore, Malaysia, Thailand, Turkey, India which are owned by Ascentawits as AST-3424.
  • GlyTechminorGTM or Marketing Partner · 23 December 2024Signed marketing promotion and material transfer agreement with Japan's GlyTech for GlycOBI® ADC key technology in the Japanese market. GlyTech serves as a marketing promotion partner for OBI's technology platform in Japan.
  • Ablexis, LLCcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2023OBI Pharma licensed 'Nectin-4 Human Antibody' rights from Ablexis, LLC in 2023. This enables OBI's development of Nectin-4 targeted ADCs including OBI-904.
  • Biosion, Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 December 2021OBI signed an exclusive license agreement for anti-TROP2 humanized monoclonal antibody (BSI04702) with Biosion for worldwide rights excluding China, Hong Kong and Macao. OBI has licensed the TROP2 targeting antibody amino acid sequence since December 2021. OBI holds worldwide commercial rights to OBI-902 and OBI-992 except for rights pertaining to the antibody in China.
  • Zhejiang Hisun Pharmaceutical Co. Ltd.coreStrategic or Co-development PartnerCollaboration on OBI-3424/AST-3424 development in China. Zhejiang Hisun Pharmaceutical holds rights in China, Hong Kong, Macao for OBI-3424/AST-3424 and has initiated a phase IIb study in HCC in collaboration with Ascentawits.

Scale indicators3 records

Recent moves13 records

Expansion highlights6 records

OBI Pharma competitors and assessment

Company assessment

Direct peers

  • ProfoundBio: Clinical-stage ADC company with proprietary conjugation technology and pipeline targeting validated oncology antigens (FRα, HER2, HER3). Closely comparable to OBI in pipeline architecture, antigen selection, and platform-based approach.
  • Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating ADCs (ISACs), a related next-generation ADC category. Comparable in clinical stage, target oncology focus, and platform-technology licensing model.
  • Pyxis Oncology: Clinical-stage ADC and antibody-drug conjugate developer with a pipeline targeting solid tumors. Closely comparable in stage, business model (out-licensing and platform partnerships), and focus on site-specific conjugation approaches.
  • Mersana Therapeutics: Clinical-stage ADC developer with proprietary Dolasynthen and Immunosynthen platforms targeting oncology. Comparable as a similarly-sized clinical-stage biotech focused exclusively on next-generation ADC conjugation technologies with no commercialized products.
  • Tubulis: Clinical-stage ADC biotech focused on differentiated conjugation chemistry and linker technologies, with lead candidates in solid tumors. Directly comparable on enabling-technology positioning and clinical-stage ADC focus.

Emerging players

  • Innovent Biologics: China-headquartered biopharmaceutical company developing next-generation ADCs (IBI354, IBI130, IBI3001) with global out-licensing ambitions. Comparable as an Asia-based clinical-stage ADC developer with platform-out-licensing strategy.
  • Hansoh Pharmaceutical: Chinese pharma with growing ADC pipeline and global BD ambitions (multiple licensing deals with big pharma in oncology). Comparable as an Asia-based emerging ADC developer pursuing similar out-licensing and partnership strategies.

Broad incumbents

  • Daiichi Sankyo: Japanese pharma leader behind the DXd ADC platform (Enhertu, Datroway with AstraZeneca). Sets the competitive benchmark for site-specific ADCs that OBI's GlycOBI® platform competes against; relevant for licensing economics and partnership dynamics.
  • Pfizer: Global pharma with major ADC franchise post-Seagen acquisition (Adcetris, Padcev, Tukysa, Tivdak). Competes directly for ADC licensing deals and represents a likely strategic acquirer or large-pharma partner for clinical-stage ADC developers.
  • AstraZeneca: Global pharma with major ADC franchise via Daiichi Sankyo partnership (Enhertu, Datroway). Represents both a potential licensor/partner for OBI's platform and a competitor pursuing similar TROP2, HER2, and HER3 targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

OBI Pharma social profiles

Digital presence

OBI Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OBI Pharma leadership team

Management profile

Number of profiles

Profiles7 records

OBI Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

OBI Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OBI Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OBI Pharma

What does OBI Pharma do?

OBI Pharma is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and prodrugs for oncology indications. Its proprietary Obrion® ADC platform and sub-platforms (GlycOBI®, GlycOBI DUO®, ThiOBI®, EndoSymeOBI®, HYPrOBI®) enable site-specific conjugation and controlled DAR for homogeneous ADCs. Lead programs include OBI-992, OBI-902 (TROP2 ADCs), OBI-3424 (AKR1C3 prodrug), OBI-999 and OBI-888 (Globo H ADCs).

Is OBI Pharma a public or private company?

OBI Pharma is a public company. It is classified as public and is currently operating.

When was OBI Pharma founded?

OBI Pharma was founded in 2002. It employs 101 to 250 people.

Where is OBI Pharma based?

OBI Pharma is headquartered in Taipei, Taiwan, in the Asia region.

How does OBI Pharma make money?

Two revenue lines are on record. Licensing and Collaboration Revenue is the primary driver. The others are no Commercialized Products.

Who are OBI Pharma's main competitors?

Direct peers on record are ProfoundBio, Bolt Biotherapeutics, Pyxis Oncology, Mersana Therapeutics and Tubulis. Emerging players are Innovent Biologics and Hansoh Pharmaceutical. Broad incumbents are Daiichi Sankyo, Pfizer and AstraZeneca.

Does OBI Pharma have an API?

No public API is recorded for OBI Pharma.

What industry is OBI Pharma in?

OBI Pharma's product category is Oncology Biopharmaceuticals (Antibody-Drug Conjugates). Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
医药魔方-致力于数据赋能医药创新,助力高效决策与数智化转型Novartis Enters ADC Arena With Over USD 2bn OBI Pharma Platform DealNovartis signed a global ADC collaboration with OBI Pharma, granting rights to OBI's conjugation technology and patents for selected payloads. OBI receives $30 million upfront, with milestones and royalties potentially exceeding $2 billion. The deal marks Novartis's first ADC partnership, diversifying its oncology pipeline.FinanzNachrichten.deOBI Pharma unterzeichnet Kooperations- und Lizenzvereinbarung mit NovartisOBI Pharma signed a cooperation and licensing agreement with Novartis to develop next-generation antibody-drug conjugates using its proprietary platforms. Novartis receives exclusive rights to certain drug classes, with OBI receiving a $30 million upfront payment and milestone payments totaling over $2 billion. The deal also includes tiered royalties on net sales of licensed products.TradingViewOBI Pharma Gets $30M Upfront in Novartis ADC Deal Worth Over $2BOBI Pharma received a $30M upfront payment from Novartis in a licensing deal for its ADC platform, with total potential value exceeding $2B. The deal includes tiered royalties and gives Novartis worldwide exclusive rights for selected payload classes, though specific product candidates and milestone triggers were not disclosed.TradingViewOBI Pharma Gets $30M Upfront in Novartis Deal With Over $2B PotentialOBI Pharma will receive $30M upfront under an ADC collaboration with Novartis, with development, regulatory, and commercial milestones bringing total potential value to over $2B plus tiered royalties. Novartis gets exclusive worldwide rights for selected payload classes, but no prior-period comparison was provided.The SpectrumOBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of CholangiocarcinomaOBI Pharma received Orphan Drug Designation from the US FDA for OBI-902, a TROP2-targeted antibody-drug conjugate for treating cholangiocarcinoma, a rare and lethal malignancy with a 5-year survival rate between 2% and 23%. The designation, granted in August 2025 when the company launched a Phase I/II clinical trial in the US and Taiwan, provides regulatory incentives including tax credits, user fee exemptions, and marketing exclusivity. OBI Pharma holds worldwide commercial rights to OBI-902 except in China, where Biosion retains exclusive rights to the TROP2 antibody sequence under a 2021 licensing agreement.The Hutchinson NewsOBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of CholangiocarcinomaOBI Pharma announced that its TROP2-targeted antibody-drug conjugate OBI-902 has received Orphan Drug Designation from the US FDA for the treatment of cholangiocarcinoma, a rare and lethal malignancy with a 5-year survival rate between 2% and 23%. OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based site-specific conjugation technology and is currently under evaluation in a Phase I/II clinical trial launched in August 2025 across the United States and Taiwan. The Orphan Drug Designation qualifies OBI for incentives including tax credits for clinical trials, exemption from user fees, and marketing exclusivity, with no FDA-approved ADC therapies currently available for cholangiocarcinoma.The Northwest Florida Daily NewsOBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of CholangiocarcinomaOBI Pharma, a clinical-stage oncology company headquartered in Taiwan, received Orphan Drug Designation from the US FDA for OBI-902, a TROP2-targeted antibody-drug conjugate for treating cholangiocarcinoma, a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate of 2-23%. OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based technology to enter clinical evaluation, with a Phase I/II trial launched in August 2025 in the United States and Taiwan. The Orphan Drug Designation provides OBI Pharma with incentives including tax credits for clinical trials, exemption from user fees, and marketing exclusivity.azcentralOBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of CholangiocarcinomaOBI Pharma received Orphan Drug Designation from the US FDA for OBI-902, an antibody-drug conjugate intended to treat cholangiocarcinoma. This designation provides incentives such as tax credits and marketing exclusivity to encourage development of therapies for this rare malignancy with limited treatment options. The company has already launched a Phase I/II clinical trial in the United States and Taiwan to evaluate the drug's safety and efficacy.GlobeNewswireOBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid TumorsOBI Pharma initiated a Phase 1/2 clinical trial of OBI-902, a TROP2-targeted antibody-drug conjugate, in advanced solid tumors. The IND was cleared by the U.S. FDA on April 30, 2025, and the study aims to verify safety, pharmacokinetics, and preliminary efficacy. The trial is led by Apostolia M. Tsimberidou of MD Anderson Cancer Center.GlobeNewswireOBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADCOBI Pharma announced the U.S. FDA cleared its IND application for OBI-902, a Trop-2-targeted ADC, to begin a Phase 1/2 study in advanced solid tumors. The trial is planned to start enrolling patients in H2 2025, following IND submission on March 31 and clearance on April 30, 2025.